why would a generic have lower safety and efficacy?
why couldn’t oncologists prescribe Zantrene and the generic version of Carfilzomib together?
There is something ethically stinky about this patent protection for big pharma.
Is it correct that it typically costs $300,000 US for carfilzomib treatment per patient per annum ? And that an identical generic version would cost peanuts?
To me, it seems a patent rort, and capers like this give capitalism a bad name. the concept of capitalism is beautiful, but once the winners get to a certain size, they are powerful enough to stop the natural capitalistic principles of fair competition from operating.
who wants big Pharma to rule the world? has it that good for anyone?
Ann: Expanded Heart Protection Discovery for Zantrene, page-150
-
- There are more pages in this discussion • 237 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.030(2.10%) |
Mkt cap ! $238.5M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.46 | $1.38 | $123.1K | 87.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19987 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 330 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |